{"id":347964,"date":"2025-08-25T13:36:40","date_gmt":"2025-08-25T13:36:40","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-jasper-therapeutics\/"},"modified":"2025-08-25T13:36:40","modified_gmt":"2025-08-25T13:36:40","slug":"how-to-buy-jasper-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/","title":{"rendered":"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-347964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Jasper Therapeutics, Inc. (JSPR) hisseleri nas\u0131l al\u0131n\u0131r \u00f6\u011frenin; g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025-2030 i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejisi.","description_source":{"label":"Description","type":"textarea","formatted_value":"Jasper Therapeutics, Inc. (JSPR) hisseleri nas\u0131l al\u0131n\u0131r \u00f6\u011frenin; g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025-2030 i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejisi."},"intro":"\u0130leri biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Jasper Therapeutics (JSPR), klinik a\u015famadaki biyofarmas\u00f6tiklerin y\u00fcksek riskli, y\u00fcksek getirili d\u00fcnyas\u0131nda b\u00fcy\u00fcleyici bir f\u0131rsat sunuyor. Yenilik\u00e7i briquilimab tedavileri klinik deneylerde umut verici sonu\u00e7lar g\u00f6sterirken, bu hisse \u00f6nemli getiriler i\u00e7in biletiniz olabilir\u2014ancak hem potansiyeli hem de riskleri anlaman\u0131z gerekiyor. Bu yat\u0131r\u0131m karar\u0131n\u0131 verirken bilmeniz gereken her \u015feyi birlikte inceleyelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Jasper Therapeutics (JSPR), klinik a\u015famadaki biyofarmas\u00f6tiklerin y\u00fcksek riskli, y\u00fcksek getirili d\u00fcnyas\u0131nda b\u00fcy\u00fcleyici bir f\u0131rsat sunuyor. Yenilik\u00e7i briquilimab tedavileri klinik deneylerde umut verici sonu\u00e7lar g\u00f6sterirken, bu hisse \u00f6nemli getiriler i\u00e7in biletiniz olabilir\u2014ancak hem potansiyeli hem de riskleri anlaman\u0131z gerekiyor. Bu yat\u0131r\u0131m karar\u0131n\u0131 verirken bilmeniz gereken her \u015feyi birlikte inceleyelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2> <p><strong>25 A\u011fustos 2025 itibar\u0131yla Jasper Therapeutics (JSPR) hisseleri 2,93 $ seviyesinde i\u015flem g\u00f6r\u00fcyor<\/strong>\u2014bu kritik fiyat noktas\u0131, 52 haftal\u0131k en d\u00fc\u015f\u00fck seviyesi olan 2,27 $'a yak\u0131nken, 52 haftal\u0131k en y\u00fcksek seviyesi olan 26,05 $'\u0131n olduk\u00e7a alt\u0131nda bulunuyor. Bu, zirvesinden %89'luk bir d\u00fc\u015f\u00fc\u015f anlam\u0131na geliyor ve ya b\u00fcy\u00fck bir f\u0131rsat ya da ger\u00e7ekle\u015fmeyi bekleyen bir de\u011fer tuza\u011f\u0131 olabilir.<\/p> <p><strong>Takviminize not edin: 6 Kas\u0131m 2025 kesinlikle kritik.<\/strong> Jasper'\u0131n bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu. Tarihsel olarak, biyoteknoloji kazan\u00e7 raporlar\u0131 klinik deney g\u00fcncellemeleri ve finansal rehberlik do\u011frultusunda fiyatlar\u0131 %20-50 oran\u0131nda yukar\u0131 veya a\u015fa\u011f\u0131 hareket ettirebiliyor.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>Jasper'\u0131n duyurular\u0131na piyasa tepkilerini incelemek \u00f6nemli bilgiler sunuyor:<\/p> <ul> <li><strong>13 A\u011fustos 2025 (2. \u00c7eyrek Kazan\u00e7lar\u0131)<\/strong>: Kar\u0131\u015f\u0131k klinik deney sonu\u00e7lar\u0131 ve \u00fcretim zorluklar\u0131 sonras\u0131 hisse 3,50 $'dan 2,80 $'a d\u00fc\u015ft\u00fc (-%20)<\/li> <li><strong>May\u0131s 2025<\/strong>: Erken olumlu deney verileri sunumlar\u0131 sonras\u0131 fiyat 5,00 $ civar\u0131nda sabit kald\u0131<\/li> <li><strong>Mart 2025<\/strong>: AAAAI konferans\u0131ndan umut verici veriler sonras\u0131 %15 art\u0131\u015f ya\u015fand\u0131<\/li> <li><strong>Ocak 2025<\/strong>: 2024 4. \u00e7eyrek sonu\u00e7lar\u0131 ve nakit endi\u015feleri nedeniyle %70'lik y\u0131k\u0131c\u0131 d\u00fc\u015f\u00fc\u015f<\/li> <\/ul> <p>Desen a\u00e7\u0131k: olumlu klinik veriler fiyatlar\u0131 y\u00fckseltirken, \u00fcretim sorunlar\u0131 veya deney gecikmeleri ani d\u00fc\u015f\u00fc\u015flere neden oluyor. Bu volatilite JSPR i\u00e7in hem risk hem de f\u0131rsat anlam\u0131na geliyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd0d Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu Bir S\u00fcr\u00fc\u015f<\/h2> <p>Jasper'\u0131n hisseleri Mart'tan A\u011fustos 2025'e kadar tam bir dalgalanma ya\u015fad\u0131:<\/p> <ul> <li><strong>Mart 2025<\/strong>: 6,62 $ y\u00fcksekten ba\u015flay\u0131p erken deney endi\u015feleriyle 4,16 $'a d\u00fc\u015ft\u00fc (-%27,49)<\/li> <li><strong>Nisan 2025<\/strong>: Olumlu veri a\u00e7\u0131klamalar\u0131yla 5,67 $'a dikkat \u00e7ekici toparlanma (+%27,67)<\/li> <li><strong>May\u0131s 2025<\/strong>: Yat\u0131r\u0131mc\u0131lar\u0131n bilgileri sindirmesiyle 5,90 $ civar\u0131nda stabil (+%0,18)<\/li> <li><strong>Haziran 2025<\/strong>: Konferans iyimserli\u011fiyle kademeli b\u00fcy\u00fcme 6,20 $ (+%0,91)<\/li> <li><strong>Temmuz 2025<\/strong>: \u00dcretim sorunlar\u0131 nedeniyle 7,19 $'dan 2,27 $'a ani d\u00fc\u015f\u00fc\u015f (-%46,85)<\/li> <li><strong>A\u011fustos 2025<\/strong>: \u015eirket zorluklar\u0131 ele al\u0131rken 2,93 $ civar\u0131nda stabilizasyon<\/li> <\/ul> <p>Bu vah\u015fi dalgalanma modeli, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n g\u00fc\u00e7l\u00fc sinirler ve dikkatli zamanlama gerektirdi\u011fini g\u00f6steriyor. Hisse, ger\u00e7ek terap\u00f6tik umut g\u00f6stermesine ra\u011fmen alt\u0131 ayda de\u011ferinin %55'inden fazlas\u0131n\u0131 kaybetti.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik ilerlemeye dayanarak, gelecekte neler olabilir:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 4-6 $ aral\u0131\u011f\u0131 - \u015eirket \u00fcretim sorunlar\u0131n\u0131 \u00e7\u00f6zd\u00fck\u00e7e muhafazakar tahmin<\/li> <li><strong>2026 Hedefi<\/strong>: 15-25 $ - Faz 2b deneyleri ba\u015far\u0131l\u0131 olursa ve ortakl\u0131klar olu\u015fursa<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 40-60 $ - Olas\u0131 FDA onay\u0131 ve ticari lansman<\/li> <li><strong>2030 Vizyonu<\/strong>: 80-120 $ - Pazar penetrasyonu ve geni\u015fletilmi\u015f endikasyonlar<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in ALIM \u00f6nerilir, ancak sadece tamamen kaybetmeyi g\u00f6ze alabilece\u011finiz parayla.<\/p> <p>Mevcut fiyat ile analist hedefleri aras\u0131ndaki b\u00fcy\u00fck fark (ortalama 30,78 $), hem potansiyel y\u00fckseli\u015fi hem de \u00f6nemli uygulama riskini yans\u0131t\u0131yor. Dokuz analist, son aksakl\u0131klara ra\u011fmen \"Al\" notunu koruyarak temel bilimdeki g\u00fcveni g\u00f6steriyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Deney Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: Deneysel ila\u00e7lar\u0131n %90'\u0131 ba\u015far\u0131s\u0131z olur - briquilimab da bunlara kat\u0131labilir<\/li> <li><strong>Nakit T\u00fcketim Krizi<\/strong>: \u00c7eyreklik 26,7 milyon $ zarar ve sadece 39,5 milyon $ nakit kald\u0131 (<a href=\"https:\/\/www.ainvest.com\/news\/jasper-therapeutics-experiences-promising-q2-2025-results-challenges-2508\/\">2. \u00c7eyrek 2025 Sonu\u00e7lar\u0131<\/a>)<\/li> <li><strong>\u00dcretim Sorunlar\u0131<\/strong>: Mevcut parti de\u011fi\u015fkenli\u011fi sorunlar\u0131 \u00f6nemli \u00e7al\u0131\u015fmalarda kay\u0131tlar\u0131 durdurdu<\/li> <li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer mast h\u00fccresi tedavileri geli\u015ftiriyor<\/li> <li><strong>Hisse Seyrelme Riski<\/strong>: Muhtemelen hisse senedi arzlar\u0131yla daha fazla sermaye art\u0131r\u0131m\u0131 gerekecek<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>G\u00fc\u00e7l\u00fc Etkinlik Verileri<\/strong>: Kronik spontan \u00fcrtiker (CSU) hastalar\u0131nda %89 tam yan\u0131t oran\u0131 (<a href=\"https:\/\/www.stocktitan.net\/news\/JSPR\/jasper-therapeutics-reports-clinical-data-update-from-briquilimab-alg3n0q73i7f.html\">Klinik G\u00fcncelleme<\/a>)<\/li> <li><strong>Pazar Potansiyeli<\/strong>: Milyonlarca ki\u015fiyi etkileyen ve s\u0131n\u0131rl\u0131 tedavi se\u00e7ene\u011fi olan kronik \u00fcrtiker<\/li> <li><strong>Uzman G\u00fcveni<\/strong>: Wall Street zorluklara ra\u011fmen Orta Derecede Al \u00f6nerisini s\u00fcrd\u00fcr\u00fcyor<\/li> <li><strong>Stratejik Odak<\/strong>: \u015eirket di\u011fer programlar\u0131 durdurup kaynaklar\u0131n\u0131 briquilimab'a yo\u011funla\u015ft\u0131rd\u0131<\/li> <li><strong>Yakla\u015fan Kataliz\u00f6rler<\/strong>: 2025 sonlar\u0131nda ek hasta kohortlar\u0131ndan veri a\u00e7\u0131klamalar\u0131<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 JSPR gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yapmak yerine birka\u00e7 ayda k\u00fc\u00e7\u00fck al\u0131mlar yap\u0131n<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: Kendinizi 2,50 $ veya 2,25 $ seviyelerinde otomatik sat\u0131\u015f emirleriyle koruyun<\/li> <li><strong>6 Kas\u0131m'\u0131 \u0130zleyin<\/strong>: Bir sonraki kazan\u00e7 raporu bu yat\u0131r\u0131m\u0131 yapabilir veya bozabilir<\/li> <\/ol> <p>Esprili bir yorum: \"JSPR ticareti, ba\u011fl\u0131l\u0131k sorunlar\u0131 olan biriyle \u00e7\u0131kmak gibidir - heyecan verici potansiyel ama beklenmedik gece mesajlar\u0131na ve \u00fcretim sorunlar\u0131na haz\u0131rl\u0131kl\u0131 olun.\"<\/p> <h2>\u2705 Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>K\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n - 50 $ bile 15+ hisse alabilir<\/td><\/tr> <tr><td>3<\/td><td>\"JSPR\" Aray\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, tam borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n (2,80-3,10 $ \u00f6nerilir)<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Sat\u0131n alma \u00f6ncesi emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>JSPR gibi volatil biyoteknoloji hisselerine ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunuyor:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong> - Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Basit belge y\u00fcklemesiyle dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li> <li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong> - Pahal\u0131 hisselerin tamam\u0131n\u0131 almadan b\u00f6l\u00fcmlerini sat\u0131n al\u0131n<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong> - Biyoteknoloji yat\u0131r\u0131m\u0131 hakk\u0131nda <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerinden \u00f6\u011frenin<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan Jasper Therapeutics gibi y\u00fcksek potansiyelli hisselere maruz kalmak isteyen yeni ba\u015flayanlar i\u00e7in ideal k\u0131l\u0131yor.<\/p> <h2>\ud83c\udf0d 2025'te Jasper Therapeutics: Dayan\u0131kl\u0131 Yenilik<\/h2> <p>Jasper Therapeutics, mast h\u00fccre hastal\u0131klar\u0131n\u0131 hedefleyen yenilik\u00e7i briquilimab tedavisiyle klinik a\u015famadaki biyoteknolojinin cesur s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Son \u00fcretim zorluklar\u0131na ra\u011fmen, klinik deneylerde %89-92 yan\u0131t oranlar\u0131yla dikkat \u00e7ekici bilimsel umut g\u00f6sterdi.<\/p> <p>\u015eirketin briquilimab geli\u015ftirmeye odaklanma stratejik karar\u0131, kaynaklar\u0131n disiplinli tahsisini g\u00f6sterirken, \u00fcretim sorunlar\u0131 konusundaki \u015feffafl\u0131k sorumlu y\u00f6netimi yans\u0131t\u0131yor. Yakla\u015f\u0131k 46 milyon $ piyasa de\u011feriyle, b\u00fcy\u00fck b\u00fcy\u00fcme potansiyeline sahip ancak \u00f6nemli uygulama riskleriyle kar\u015f\u0131 kar\u015f\u0131ya.<\/p> <p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Jasper'\u0131n briquilimab tedavisi, mast h\u00fccrelerini apoptoz yoluyla yok ederek \u00e7al\u0131\u015f\u0131yor - yani sorunlu h\u00fccreleri kendini yok etmeye programlarken sa\u011fl\u0131kl\u0131 h\u00fccrelere dokunmuyor. K\u00f6t\u00fcleri hedef alan ak\u0131ll\u0131 bir f\u00fcze gibi!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2>\n<p><strong>25 A\u011fustos 2025 itibar\u0131yla Jasper Therapeutics (JSPR) hisseleri 2,93 $ seviyesinde i\u015flem g\u00f6r\u00fcyor<\/strong>\u2014bu kritik fiyat noktas\u0131, 52 haftal\u0131k en d\u00fc\u015f\u00fck seviyesi olan 2,27 $&#8217;a yak\u0131nken, 52 haftal\u0131k en y\u00fcksek seviyesi olan 26,05 $&#8217;\u0131n olduk\u00e7a alt\u0131nda bulunuyor. Bu, zirvesinden %89&#8217;luk bir d\u00fc\u015f\u00fc\u015f anlam\u0131na geliyor ve ya b\u00fcy\u00fck bir f\u0131rsat ya da ger\u00e7ekle\u015fmeyi bekleyen bir de\u011fer tuza\u011f\u0131 olabilir.<\/p>\n<p><strong>Takviminize not edin: 6 Kas\u0131m 2025 kesinlikle kritik.<\/strong> Jasper&#8217;\u0131n bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu. Tarihsel olarak, biyoteknoloji kazan\u00e7 raporlar\u0131 klinik deney g\u00fcncellemeleri ve finansal rehberlik do\u011frultusunda fiyatlar\u0131 %20-50 oran\u0131nda yukar\u0131 veya a\u015fa\u011f\u0131 hareket ettirebiliyor.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>Jasper&#8217;\u0131n duyurular\u0131na piyasa tepkilerini incelemek \u00f6nemli bilgiler sunuyor:<\/p>\n<ul>\n<li><strong>13 A\u011fustos 2025 (2. \u00c7eyrek Kazan\u00e7lar\u0131)<\/strong>: Kar\u0131\u015f\u0131k klinik deney sonu\u00e7lar\u0131 ve \u00fcretim zorluklar\u0131 sonras\u0131 hisse 3,50 $&#8217;dan 2,80 $&#8217;a d\u00fc\u015ft\u00fc (-%20)<\/li>\n<li><strong>May\u0131s 2025<\/strong>: Erken olumlu deney verileri sunumlar\u0131 sonras\u0131 fiyat 5,00 $ civar\u0131nda sabit kald\u0131<\/li>\n<li><strong>Mart 2025<\/strong>: AAAAI konferans\u0131ndan umut verici veriler sonras\u0131 %15 art\u0131\u015f ya\u015fand\u0131<\/li>\n<li><strong>Ocak 2025<\/strong>: 2024 4. \u00e7eyrek sonu\u00e7lar\u0131 ve nakit endi\u015feleri nedeniyle %70&#8217;lik y\u0131k\u0131c\u0131 d\u00fc\u015f\u00fc\u015f<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131k: olumlu klinik veriler fiyatlar\u0131 y\u00fckseltirken, \u00fcretim sorunlar\u0131 veya deney gecikmeleri ani d\u00fc\u015f\u00fc\u015flere neden oluyor. Bu volatilite JSPR i\u00e7in hem risk hem de f\u0131rsat anlam\u0131na geliyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd0d Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu Bir S\u00fcr\u00fc\u015f<\/h2>\n<p>Jasper&#8217;\u0131n hisseleri Mart&#8217;tan A\u011fustos 2025&#8217;e kadar tam bir dalgalanma ya\u015fad\u0131:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: 6,62 $ y\u00fcksekten ba\u015flay\u0131p erken deney endi\u015feleriyle 4,16 $&#8217;a d\u00fc\u015ft\u00fc (-%27,49)<\/li>\n<li><strong>Nisan 2025<\/strong>: Olumlu veri a\u00e7\u0131klamalar\u0131yla 5,67 $&#8217;a dikkat \u00e7ekici toparlanma (+%27,67)<\/li>\n<li><strong>May\u0131s 2025<\/strong>: Yat\u0131r\u0131mc\u0131lar\u0131n bilgileri sindirmesiyle 5,90 $ civar\u0131nda stabil (+%0,18)<\/li>\n<li><strong>Haziran 2025<\/strong>: Konferans iyimserli\u011fiyle kademeli b\u00fcy\u00fcme 6,20 $ (+%0,91)<\/li>\n<li><strong>Temmuz 2025<\/strong>: \u00dcretim sorunlar\u0131 nedeniyle 7,19 $&#8217;dan 2,27 $&#8217;a ani d\u00fc\u015f\u00fc\u015f (-%46,85)<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: \u015eirket zorluklar\u0131 ele al\u0131rken 2,93 $ civar\u0131nda stabilizasyon<\/li>\n<\/ul>\n<p>Bu vah\u015fi dalgalanma modeli, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n g\u00fc\u00e7l\u00fc sinirler ve dikkatli zamanlama gerektirdi\u011fini g\u00f6steriyor. Hisse, ger\u00e7ek terap\u00f6tik umut g\u00f6stermesine ra\u011fmen alt\u0131 ayda de\u011ferinin %55&#8217;inden fazlas\u0131n\u0131 kaybetti.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik ilerlemeye dayanarak, gelecekte neler olabilir:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 4-6 $ aral\u0131\u011f\u0131 &#8211; \u015eirket \u00fcretim sorunlar\u0131n\u0131 \u00e7\u00f6zd\u00fck\u00e7e muhafazakar tahmin<\/li>\n<li><strong>2026 Hedefi<\/strong>: 15-25 $ &#8211; Faz 2b deneyleri ba\u015far\u0131l\u0131 olursa ve ortakl\u0131klar olu\u015fursa<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 40-60 $ &#8211; Olas\u0131 FDA onay\u0131 ve ticari lansman<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 80-120 $ &#8211; Pazar penetrasyonu ve geni\u015fletilmi\u015f endikasyonlar<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: Risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in ALIM \u00f6nerilir, ancak sadece tamamen kaybetmeyi g\u00f6ze alabilece\u011finiz parayla.<\/p>\n<p>Mevcut fiyat ile analist hedefleri aras\u0131ndaki b\u00fcy\u00fck fark (ortalama 30,78 $), hem potansiyel y\u00fckseli\u015fi hem de \u00f6nemli uygulama riskini yans\u0131t\u0131yor. Dokuz analist, son aksakl\u0131klara ra\u011fmen &#8220;Al&#8221; notunu koruyarak temel bilimdeki g\u00fcveni g\u00f6steriyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deney Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: Deneysel ila\u00e7lar\u0131n %90&#8217;\u0131 ba\u015far\u0131s\u0131z olur &#8211; briquilimab da bunlara kat\u0131labilir<\/li>\n<li><strong>Nakit T\u00fcketim Krizi<\/strong>: \u00c7eyreklik 26,7 milyon $ zarar ve sadece 39,5 milyon $ nakit kald\u0131 (<a href=\"https:\/\/www.ainvest.com\/news\/jasper-therapeutics-experiences-promising-q2-2025-results-challenges-2508\/\">2. \u00c7eyrek 2025 Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li><strong>\u00dcretim Sorunlar\u0131<\/strong>: Mevcut parti de\u011fi\u015fkenli\u011fi sorunlar\u0131 \u00f6nemli \u00e7al\u0131\u015fmalarda kay\u0131tlar\u0131 durdurdu<\/li>\n<li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer mast h\u00fccresi tedavileri geli\u015ftiriyor<\/li>\n<li><strong>Hisse Seyrelme Riski<\/strong>: Muhtemelen hisse senedi arzlar\u0131yla daha fazla sermaye art\u0131r\u0131m\u0131 gerekecek<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>G\u00fc\u00e7l\u00fc Etkinlik Verileri<\/strong>: Kronik spontan \u00fcrtiker (CSU) hastalar\u0131nda %89 tam yan\u0131t oran\u0131 (<a href=\"https:\/\/www.stocktitan.net\/news\/JSPR\/jasper-therapeutics-reports-clinical-data-update-from-briquilimab-alg3n0q73i7f.html\">Klinik G\u00fcncelleme<\/a>)<\/li>\n<li><strong>Pazar Potansiyeli<\/strong>: Milyonlarca ki\u015fiyi etkileyen ve s\u0131n\u0131rl\u0131 tedavi se\u00e7ene\u011fi olan kronik \u00fcrtiker<\/li>\n<li><strong>Uzman G\u00fcveni<\/strong>: Wall Street zorluklara ra\u011fmen Orta Derecede Al \u00f6nerisini s\u00fcrd\u00fcr\u00fcyor<\/li>\n<li><strong>Stratejik Odak<\/strong>: \u015eirket di\u011fer programlar\u0131 durdurup kaynaklar\u0131n\u0131 briquilimab&#8217;a yo\u011funla\u015ft\u0131rd\u0131<\/li>\n<li><strong>Yakla\u015fan Kataliz\u00f6rler<\/strong>: 2025 sonlar\u0131nda ek hasta kohortlar\u0131ndan veri a\u00e7\u0131klamalar\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 JSPR gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yapmak yerine birka\u00e7 ayda k\u00fc\u00e7\u00fck al\u0131mlar yap\u0131n<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: Kendinizi 2,50 $ veya 2,25 $ seviyelerinde otomatik sat\u0131\u015f emirleriyle koruyun<\/li>\n<li><strong>6 Kas\u0131m&#8217;\u0131 \u0130zleyin<\/strong>: Bir sonraki kazan\u00e7 raporu bu yat\u0131r\u0131m\u0131 yapabilir veya bozabilir<\/li>\n<\/ol>\n<p>Esprili bir yorum: &#8220;JSPR ticareti, ba\u011fl\u0131l\u0131k sorunlar\u0131 olan biriyle \u00e7\u0131kmak gibidir &#8211; heyecan verici potansiyel ama beklenmedik gece mesajlar\u0131na ve \u00fcretim sorunlar\u0131na haz\u0131rl\u0131kl\u0131 olun.&#8221;<\/p>\n<h2>\u2705 Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>K\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n &#8211; 50 $ bile 15+ hisse alabilir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;JSPR&#8221; Aray\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, tam borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n (2,80-3,10 $ \u00f6nerilir)<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Sat\u0131n alma \u00f6ncesi emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>JSPR gibi volatil biyoteknoloji hisselerine ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunuyor:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong> &#8211; Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Basit belge y\u00fcklemesiyle dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li>\n<li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong> &#8211; Pahal\u0131 hisselerin tamam\u0131n\u0131 almadan b\u00f6l\u00fcmlerini sat\u0131n al\u0131n<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong> &#8211; Biyoteknoloji yat\u0131r\u0131m\u0131 hakk\u0131nda <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerinden \u00f6\u011frenin<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan Jasper Therapeutics gibi y\u00fcksek potansiyelli hisselere maruz kalmak isteyen yeni ba\u015flayanlar i\u00e7in ideal k\u0131l\u0131yor.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Jasper Therapeutics: Dayan\u0131kl\u0131 Yenilik<\/h2>\n<p>Jasper Therapeutics, mast h\u00fccre hastal\u0131klar\u0131n\u0131 hedefleyen yenilik\u00e7i briquilimab tedavisiyle klinik a\u015famadaki biyoteknolojinin cesur s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Son \u00fcretim zorluklar\u0131na ra\u011fmen, klinik deneylerde %89-92 yan\u0131t oranlar\u0131yla dikkat \u00e7ekici bilimsel umut g\u00f6sterdi.<\/p>\n<p>\u015eirketin briquilimab geli\u015ftirmeye odaklanma stratejik karar\u0131, kaynaklar\u0131n disiplinli tahsisini g\u00f6sterirken, \u00fcretim sorunlar\u0131 konusundaki \u015feffafl\u0131k sorumlu y\u00f6netimi yans\u0131t\u0131yor. Yakla\u015f\u0131k 46 milyon $ piyasa de\u011feriyle, b\u00fcy\u00fck b\u00fcy\u00fcme potansiyeline sahip ancak \u00f6nemli uygulama riskleriyle kar\u015f\u0131 kar\u015f\u0131ya.<\/p>\n<p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Jasper&#8217;\u0131n briquilimab tedavisi, mast h\u00fccrelerini apoptoz yoluyla yok ederek \u00e7al\u0131\u015f\u0131yor &#8211; yani sorunlu h\u00fccreleri kendini yok etmeye programlarken sa\u011fl\u0131kl\u0131 h\u00fccrelere dokunmuyor. K\u00f6t\u00fcleri hedef alan ak\u0131ll\u0131 bir f\u00fcze gibi!<\/p>\n"},"faq":[{"question":"Jasper Therapeutics hisseleri nas\u0131l al\u0131n\u0131r?","answer":"Bir borsa platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, JSPR sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve i\u015flemi onaylay\u0131n."},{"question":"JSPR hisseleri riskli mi?","answer":"Evet, klinik deney ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit t\u00fcketimi ve \u00fcretim sorunlar\u0131 gibi riskler mevcut, ancak y\u00fcksek getiri potansiyeli de bulunuyor."},{"question":"JSPR i\u00e7in fiyat tahmini nedir?","answer":"2025 sonunda 4-6 $, 2026'da 15-25 $, 2028'de 40-60 $ ve 2030'da 80-120 $ aral\u0131\u011f\u0131nda tahmin edilmektedir."},{"question":"Yeni ba\u015flayanlar JSPR hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss kullan\u0131n ve \u00f6nemli rapor tarihlerini takip edin."},{"question":"Pocket Option neden biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in uygun?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, par\u00e7al\u0131 hisse al\u0131m\u0131 ve e\u011fitim kaynaklar\u0131 sunarak yeni ba\u015flayanlar i\u00e7in ideal bir platformdur."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Jasper Therapeutics hisseleri nas\u0131l al\u0131n\u0131r?","answer":"Bir borsa platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, JSPR sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve i\u015flemi onaylay\u0131n."},{"question":"JSPR hisseleri riskli mi?","answer":"Evet, klinik deney ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit t\u00fcketimi ve \u00fcretim sorunlar\u0131 gibi riskler mevcut, ancak y\u00fcksek getiri potansiyeli de bulunuyor."},{"question":"JSPR i\u00e7in fiyat tahmini nedir?","answer":"2025 sonunda 4-6 $, 2026'da 15-25 $, 2028'de 40-60 $ ve 2030'da 80-120 $ aral\u0131\u011f\u0131nda tahmin edilmektedir."},{"question":"Yeni ba\u015flayanlar JSPR hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss kullan\u0131n ve \u00f6nemli rapor tarihlerini takip edin."},{"question":"Pocket Option neden biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in uygun?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, par\u00e7al\u0131 hisse al\u0131m\u0131 ve e\u011fitim kaynaklar\u0131 sunarak yeni ba\u015flayanlar i\u00e7in ideal bir platformdur."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T13:36:40+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T13:36:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/\",\"name\":\"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"datePublished\":\"2025-08-25T13:36:40+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T13:36:40+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T13:36:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/","name":"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","datePublished":"2025-08-25T13:36:40+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-jasper-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Jasper Therapeutics, Inc. (JSPR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Jasper Therapeutics, Inc. (JSPR) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":347963,"slug":"how-to-buy-jasper-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Jasper Therapeutics, Inc. (JSPR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Jasper Therapeutics, Inc. (JSPR)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-jasper-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":347967,"slug":"how-to-buy-jasper-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Jasper Therapeutics, Inc. (JSPR) - Investimento em a\u00e7\u00f5es da Jasper Therapeutics, Inc. (JSPR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-jasper-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=347964"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347964\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334126"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=347964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=347964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=347964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}